The serostatus approach to fighting the HIV epidemic: Prevention strategies for infected individuals

American Journal of Public Health

Volumn 91, Issue 7, 2001, Pages 1019-1024

  Janssen, R S ^a   Holtgrave, D R ^a   Valdiserri, R O ^a   Shepherd, M ^a   Gayle, H D ^a   De Cock, K M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE TRANSMISSION; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; REVIEW; RISK ASSESSMENT; SEROPREVALENCE;

EID: 0034968576     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.91.7.1019     Document Type: Review

References (60)

1. Trends in HIV incidence among young adults in the United States
2. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome
3. Prevalence of sexual and drug-related HIV risk behaviors in the US adult population: Results of the 1996 National Household Survey on Drug Abuse
4. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
5. Drug abuse treatment as AIDS prevention
6. Survival after introduction of HAART in people with known duration of HIV-1 infection
7. Extrapolating long-term HIV/AIDS survival in the post-HAART era
8. Births and deaths: Preliminary data for 1998
9. Effect of knowledge of human immunodeficiency virus infection status on sexual activity among homosexual men
10. Sexual behavior of individuals infected with the human immunodeficiency virus: The need for intervention
11. Living with HIV: Experiences and perspectives of HIV-infected sexually transmitted disease clinic patients after posttest counseling
12. Evidence for the effects of HIV antibody counseling and testing on risk behaviors
13. Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV-negative, HIV-positive and untested
14. Maternal viral load and perinatal HIV-1 subtype E transmission, Bangkok, Thailand
15. Risk factors for perinatal transmission of human immunodeficiency virus type I in women treated with zidovudine
16. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
17. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion
18. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients
19. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients
20. Heterosexual HIV-1 transmission and viral load in hemophilic patients
21. Viral load and heterosexual transmission of human immunodeficiency virus type 1
22. Virologic determinants of heterosexual transmission in Africa
23. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire
24. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors
25. Quantification of HIV in semen: Correlation with antiviral treatment and immune status
26. Effect of antiviral treatment on the shedding of HIV-1 in semen
27. Human immunodeficiency virus type 1 in the semen of men receiving highly active anti-retroviral therapy
28. Mucosal transmission of simian immunodeficiency virus
29. Vaginal transmission of SIV: Assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks
30. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
31. Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial
32. A review of protease inhibitor use in 89 pregnancies
33. Trends to reduce perinatal HIV transmission in New York City
34. Transmission dynamics of HIV infection
35. Promoting early HIV diagnosis and entry into care
36. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras
37. On-site, rapid HIV testing with same-day results and counseling
38. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings
39. HIV counseling, testing, and referral guidelines
40. Name-based surveillance and public health interventions for persons with HIV infection
41. Trillion virion delay: Time from testing positive for HIV to presentation for primary care
42. The care of HIV-infected adults in the United States
43. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps
44. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drag reactions
45. HIV-1 drug resistance in newly infected individuals
46. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
47. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
48. Are at-risk populations less concerned about HIV infection in the HAART era?
49. Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-1997
50. Reducing sexual transmission of HIV from those who know they are infected: The need for personal and collective responsibility
51. Resurgent bacterial sexually transmitted disease among men who have sex with men - King County, Washington, 1997-1999
52. Behavioral and biologic evidence of persistent high-risk behavior in an HIV primary care population
53. Role of the primary infection in epidemics of HIV infection in gay cohorts
54. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
55. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs